Bausch Health Companies Inc.
No SEC Form 4 filings for $BHC in the last 30 days.
See all $BHC insider activity →Toronto’s TSX hit another record, up 97.15 points to 36,759.29, led by telecom and tech. Canadian dollar weakened to 71.78 US cents. Earnings: Stantec beat adjusted profit, CCL topped sales; Pan American Silver missed. Brookfield, TELUS and Rogers reported results. On Wall Street, S&P 500 and Nasdaq reached highs; Cisco fell after results; CPI rose 0.1% m/m.
Canada’s TSX traded near record highs but slipped 68.19 points to 36,593.95 as investors weighed earnings and softer U.S. PPI. The Canadian dollar fell to 71.72 U.S. cents. CCL Industries rose 3.7% after beating sales; Pan American Silver fell 10% after missing profit. Brookfield’s distributable EPS rose, shares little changed.
Bausch Health Companies (BHC) shares rose nearly 40% in July after a Canada regulatory update and a beat-and-raise quarter. Prokedi was added to Quebec’s formulary. In Q2, revenue and adjusted results improved, with adjusted EPS $1.26 vs $1.23 expected, and net income $476M. Bausch raised 2026 revenue to $10.79B-$11.04B and adjusted EBITDA to $4.05B-$4.18B.
Over the past 7 days, alphai's AI scored 4 news stories mentioning BHC (Bausch Health Companies Inc.). Coverage has skewed bullish: 2 bullish, 2 neutral, and 0 bearish.
Recent BHC coverage spans earnings, market movers and corporate actions.
The article provides only a price change, with no earnings details, so the catalyst is unclear.
The move is modest and appears to be part of the broader earnings-driven tape rather than a standalone catalyst in the text.
Regulatory formulary addition plus a Q2 beat and raised full-year guidance likely supports continued upside bias, but the move is already largely reflected after the ~40% July run.
Board appointment is a governance/control signal rather than an operating or financial change.
Raised 2026 topline and profitability outlook, but 2H 2026 gross-to-net and exclusivity pressures increase earnings volatility.
alphai scores every news story that mentions BHC with an AI model for sentiment and relevance, and aggregates insider trades from Bausch Health Companies Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Toronto’s TSX hit another record, up 97.15 points to 36,759.29, led by telecom and tech. Canadian dollar weakened to 71.78 US cents. Earnings: Stantec beat adjusted profit, CCL topped sales; Pan American Silver missed. Brookfield, TELUS and Rogers reported results. On Wall Street, S&P 500 and Nasdaq reached highs; Cisco fell after results; CPI rose 0.1% m/m.
4 min readCanada’s TSX traded near record highs but slipped 68.19 points to 36,593.95 as investors weighed earnings and softer U.S. PPI. The Canadian dollar fell to 71.72 U.S. cents. CCL Industries rose 3.7% after beating sales; Pan American Silver fell 10% after missing profit. Brookfield’s distributable EPS rose, shares little changed.
6 min readBausch Health Companies (BHC) shares rose nearly 40% in July after a Canada regulatory update and a beat-and-raise quarter. Prokedi was added to Quebec’s formulary. In Q2, revenue and adjusted results improved, with adjusted EPS $1.26 vs $1.23 expected, and net income $476M. Bausch raised 2026 revenue to $10.79B-$11.04B and adjusted EBITDA to $4.05B-$4.18B.
6 min readBausch Health Companies Inc. (NYSE:BHC) said CEO Thomas J. Appio was appointed to the board of Bausch + Lomb Corporation (NYSE:BLCO), effective Aug. 5, 2026. Other directors also joined, replacing several who resigned. Bausch Health said it holds about 87% of Bausch + Lomb’s common shares indirectly and supports its strategy.
2 min readBausch Health (NYSE:BHC) reported Q2 2026 results excluding Bausch + Lomb: revenue $1.458B (+16%), adjusted EBITDA $865M (+28%), margin 59.3% (+530 bps), and adjusted operating cash flow $471M. Net debt fell to $13.7B. Full-year 2026 guidance was raised. Headwinds include Aplenzin LOE and CMS rebate impacts.
6 min readBausch Health Companies Inc. (BHC) shares rose about 13.6% after Q2 results and an improved 2026 outlook, according to the article. Q2 non-GAAP EPS was $1.26 vs $1.01 consensus, revenue $2.85B vs $2.66B. The company reported free cash flow around $593M and lifted 2026 guidance to revenue $10.79B-$11.04B and adjusted EBITDA $4.05B-$4.175B.
6 min readBausch Health Companies Inc. (BHC) shares rose about 13.6% after Q2 results beat expectations and 2026 guidance was raised, according to the article. Q2 revenue was about $2.85B vs $2.66B expected, non-GAAP EPS $1.26 vs $1.01, with $670M operating cash flow and $593M free cash flow. The stock moved from the $4s to near $6.9.
6 min readBausch Health Companies Inc. (BHC) shares rose about 13.6% after the company reported Q2 results and raised 2026 guidance, according to the article. Q2 revenue was $2.85B and non-GAAP EPS $1.26. 2026 outlook calls for revenue of $10.79B to $11.04B and adjusted EBITDA of $4.05B to $4.175B.
6 min readBausch Health (NYSE:BHC) climbed by 28.85 percent on Thursday to end at $6.03 apiece, after announcing a strong second quarter of the year that set the ground for the company’s profit recovery. In an updated report, the pharmaceutical giant said that it swung to a net income of $260 million during the period, marking a 103 percent jump from the $128 million in the same period last year, and helping slash its net loss to $1.171 billion from the $1.431 billion in the previous quarter of the year.
4 min readToday's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.
6 min read
